Abstract
Animals suffering from malignancy or chronic infection develop characteristic metabolic abnormalities, including a well-defined hypertriglyceridemic state. These abnormalities have been attributed to release of one or more mediators from activated macrophages. We report that cancer patients receiving RIFN-gamma, a potent macrophage activator, at doses of greater than or equal to 0.25 mg/m2/d i.m. show marked increases in triglyceride but not in cholesterol levels (pretreatment triglyceride level of 180 +/- 190 mg/dl [mean +/- SD] vs. a day-14 level of 370 +/- 242 mg/dl, n = 23, p less than 0.001 by the paired t test). This hypertriglyceridemia was characterized by an increase in very low-density lipoproteins and a decrease in plasma post- heparin lipase activity, consistent with defective triglyceride clearance (mean pretreatment lipase level of 2.1 mumol/ml/h vs. a day- 14 level of 1.2 mumol/ml/h, n = 6, p = 0.02 by the paired t test). rIFN- gamma did not directly inhibit lipoprotein lipase enzymatic activity in vitro. Other possible mechanisms of action, such as suppression of lipase by an rIFN-gamma-induced mediator released from activated macrophages, or a direct effect of interferon on lipase biosynthesis, require further investigation. Our observations provide evidence that factors produced by the immune system can regulate lipid metabolism in man.
Full Text
The Full Text of this article is available as a PDF (603.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bagby G. J., Spitzer J. A. Lipoprotein lipase activity in rat heart and adipose tissue during endotoxic shock. Am J Physiol. 1980 Mar;238(3):H325–H330. doi: 10.1152/ajpheart.1980.238.3.H325. [DOI] [PubMed] [Google Scholar]
- Barclay M., Skipski V. P., Terebus-Kekish O., Merker P. L., Cappuccino J. G. Serum lipoproteins in rats with tumors induced by 9,10-dimethyl-1,2-benzanthracene and with transplanted Walker carcinosarcoma 256. Cancer Res. 1967 Jun;27(6):1158–1167. [PubMed] [Google Scholar]
- Beisel W. R. Metabolic response to infection. Annu Rev Med. 1975;26:9–20. doi: 10.1146/annurev.me.26.020175.000301. [DOI] [PubMed] [Google Scholar]
- Beutler B. A., Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol. 1985 Dec;135(6):3969–3971. [PubMed] [Google Scholar]
- Beutler B., Greenwald D., Hulmes J. D., Chang M., Pan Y. C., Mathison J., Ulevitch R., Cerami A. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985 Aug 8;316(6028):552–554. doi: 10.1038/316552a0. [DOI] [PubMed] [Google Scholar]
- Beutler B., Mahoney J., Le Trang N., Pekala P., Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med. 1985 May 1;161(5):984–995. doi: 10.1084/jem.161.5.984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Boraschi D., Censini S., Tagliabue A. Interferon-gamma reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production. J Immunol. 1984 Aug;133(2):764–768. [PubMed] [Google Scholar]
- Brenneman D. E., Mathur S. N., Spector A. A. Characterization of the hyperlipidemia in mice bearing the Ehrlich ascites tumor. Eur J Cancer. 1975 Apr;11(4):225–230. doi: 10.1016/0014-2964(75)90002-x. [DOI] [PubMed] [Google Scholar]
- Farshtchi D., Lewis V. J. Effects of three bacterial infections on serum lipids of rabbits. J Bacteriol. 1968 May;95(5):1615–1621. doi: 10.1128/jb.95.5.1615-1621.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gray P. W., Goeddel D. V. Structure of the human immune interferon gene. Nature. 1982 Aug 26;298(5877):859–863. doi: 10.1038/298859a0. [DOI] [PubMed] [Google Scholar]
- Gray P. W., Leung D. W., Pennica D., Yelverton E., Najarian R., Simonsen C. C., Derynck R., Sherwood P. J., Wallace D. M., Berger S. L. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature. 1982 Feb 11;295(5849):503–508. doi: 10.1038/295503a0. [DOI] [PubMed] [Google Scholar]
- Grossberg S. E., O'Leary W. M. Hyperlipaemia following viral infection in the chicken embryo: a new syndrome. Nature. 1965 Dec 4;208(5014):954–956. doi: 10.1038/208954a0. [DOI] [PubMed] [Google Scholar]
- HIRSCH R. L., MCKAY D. G., TRAVERS R. I., SKRALY R. K. HYPERLIPIDEMIA, FATTY LIVER, AND BROMSULFOPHTHALEIN RETENTION IN RABBITS INJECTED INTRAVENOUSLY WITH BACTERIAL ENDOTOXINS. J Lipid Res. 1964 Oct;5:563–568. [PubMed] [Google Scholar]
- KARNOFSKY D. A. Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmacol Ther. 1961 Nov-Dec;2:709–712. doi: 10.1002/cpt196126709. [DOI] [PubMed] [Google Scholar]
- Kaufmann R. L., Matson C. F., Beisel W. R. Hypertriglyceridemia produced by endotoxin: role of impaired triglyceride disposal mechanisms. J Infect Dis. 1976 May;133(5):548–555. doi: 10.1093/infdis/133.5.548. [DOI] [PubMed] [Google Scholar]
- Kaufmann R. L., Matson C. F., Rowberg A. H., Beisel W. R. Defective lipid disposal mechanisms during bacterial infection in rhesus monkeys. Metabolism. 1976 Jun;25(6):615–624. doi: 10.1016/0026-0495(76)90058-5. [DOI] [PubMed] [Google Scholar]
- Kawakami M., Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med. 1981 Sep 1;154(3):631–639. doi: 10.1084/jem.154.3.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kawakami M., Pekala P. H., Lane M. D., Cerami A. Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A. 1982 Feb;79(3):912–916. doi: 10.1073/pnas.79.3.912. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kinnunen P. K. Purification of bovine milk lipoprotein lipase with the aid of detergent. Med Biol. 1977 Jun;55(3):187–191. [PubMed] [Google Scholar]
- Kurzrock R., Quesada J. R., Talpaz M., Hersh E. M., Reuben J. M., Sherwin S. A., Gutterman J. U. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol. 1986 Jul;4(7):1101–1109. doi: 10.1200/JCO.1986.4.7.1101. [DOI] [PubMed] [Google Scholar]
- Kurzrock R., Rosenblum M. G., Sherwin S. A., Rios A., Talpaz M., Quesada J. R., Gutterman J. U. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res. 1985 Jun;45(6):2866–2872. [PubMed] [Google Scholar]
- Nathan C. F., Horowitz C. R., de la Harpe J., Vadhan-Raj S., Sherwin S. A., Oettgen H. F., Krown S. E. Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8686–8690. doi: 10.1073/pnas.82.24.8686. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nathan C. F., Murray H. W., Wiebe M. E., Rubin B. Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983 Sep 1;158(3):670–689. doi: 10.1084/jem.158.3.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nilsson-Ehle P., Garfinkel A. S., Schotz M. C. Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem. 1980;49:667–693. doi: 10.1146/annurev.bi.49.070180.003315. [DOI] [PubMed] [Google Scholar]
- Pekala P. H., Kawakami M., Angus C. W., Lane M. D., Cerami A. Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A. 1983 May;80(9):2743–2747. doi: 10.1073/pnas.80.9.2743. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rinderknecht E., O'Connor B. H., Rodriguez H. Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation. J Biol Chem. 1984 Jun 10;259(11):6790–6797. [PubMed] [Google Scholar]
- Rouzer C. A., Cerami A. Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal. Mol Biochem Parasitol. 1980 Oct;2(1):31–38. doi: 10.1016/0166-6851(80)90046-8. [DOI] [PubMed] [Google Scholar]
- Sakaguchi O., Sakaguchi S. Alterations of lipid metabolism in mice injected with endotoxin. Microbiol Immunol. 1979;23(2):71–85. doi: 10.1111/j.1348-0421.1979.tb00443.x. [DOI] [PubMed] [Google Scholar]
- Svedersky L. P., Nedwin G. E., Goeddel D. V., Palladino M. A., Jr Interferon-gamma enhances induction of lymphotoxin in recombinant interleukin 2-stimulated peripheral blood mononuclear cells. J Immunol. 1985 Mar;134(3):1604–1608. [PubMed] [Google Scholar]
- Voyta J. C., Vainio P., Kinnunen P. K., Gotto A. M., Jr, Sparrow J. T., Smith L. C. Interaction of synthetic N-5-dimethylaminonaphthalene-1-sulfonyl-apolipoprotein C-II peptides with lipoprotein lipase. J Biol Chem. 1983 Mar 10;258(5):2934–2939. [PubMed] [Google Scholar]
- Wang C. S., Bass H. B., Downs D., Whitmer R. K. Modified heparin-Sepharose procedure for determination of plasma lipolytic activities of normolipidemic and hyperlipidemic subjects after injection of heparin. Clin Chem. 1981 May;27(5):663–668. [PubMed] [Google Scholar]
- Werner M. Serum protein changes during the acute phase reaction. Clin Chim Acta. 1969 Aug;25(2):299–305. doi: 10.1016/0009-8981(69)90272-1. [DOI] [PubMed] [Google Scholar]
- Zoumbos N. C., Gascon P., Djeu J. Y., Young N. S. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A. 1985 Jan;82(1):188–192. doi: 10.1073/pnas.82.1.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Tol A., van Gent T., Jansen H. Degradation of high density lipoprotein by heparin-releasable liver lipase. Biochem Biophys Res Commun. 1980 May 14;94(1):101–108. doi: 10.1016/s0006-291x(80)80193-8. [DOI] [PubMed] [Google Scholar]